Since soluble IL-6 is shed, among others, from neutrophils by ADAM10- and ADAM17-mediated proteolysis [402,403], inhibition of these proteolytic enzymes is expected to have a beneficial outcome in cancer [404]. Here, IL6 is linked to cancer.